title: The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline.
abstract: This guideline for the use of immunoglobulin (IG) for sensitized patients undergoing solid organ transplantation (SOT) is an initiative of the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of Canada to (1) provide guidance for Canadian practitioners involved in the care of patients undergoing SOT and transfusion medicine specialists on the use of IG and (2) standardize care, limit adverse events, and optimize patient care. A systematic expert and bibliography literature search up to July 2008 was conducted, with 791 literature citations and 45 reports reviewed. To validate the recommendations, the guideline was sent to physicians involved in SOT in Canada and a patient representative. The recommendations identify (1) sensitized patients undergoing SOT that would have a better survival and decreased morbidity by receiving IG preoperatively, postoperatively, and for the treatment of organ rejection; (2) patients who may not have any benefit from receiving IG; and (3) potential adversities to IG.
authors: Department of Medicine, University of Toronto, Canadian Blood Services, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, Canada. shehatan@smh.toronto.on.ca
authors: Nadine
authors: N
authors: Shehata
authors: Valerie A
authors: VA
authors: Palda
authors: Ralph M
authors: RM
authors: Meyer
authors: Tom D
authors: TD
authors: Blydt-Hansen
authors: Patricia
authors: P
authors: Campbell
authors: Carl
authors: C
authors: Cardella
authors: Steven
authors: S
authors: Martin
authors: Peter
authors: P
authors: Nickerson
authors: Kevork
authors: K
authors: Peltekian
authors: Heather
authors: H
authors: Ross
authors: Tom K
authors: TK
authors: Waddell
authors: Lori
authors: L
authors: West
authors: David
authors: D
authors: Anderson
authors: John
authors: J
authors: Freedman
authors: Heather
authors: H
authors: Hume
mesh_terms: D002170:Canada; D019317:Evidence-Based Medicine; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000494:pharmacology*; D016377:Organ Transplantation; D017410:Practice Guidelines as Topic
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors